Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study.
Basophils
eosinophils
interleukin-5 receptor α monoclonal antibody
oral corticosteroids (OCS)
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
13
5
2020
Statut:
ppublish
Résumé
Benralizumab is a humanized, fucosylated, monoclonal antibody that targets the interleukin 5 (IL-5) α receptor. Several phase III trials have shown that benralizumab can significantly reduce the incidence of acute exacerbations and improve lung function in patients with severe asthma. However, there is a paucity of data from clinical practice. In this prospective study, we evaluated the effectiveness and safety of benralizumab for severe asthma in clinical practice. This was a prospective, open-label, single-arm, single-center study in patients with severe asthma in clinical practice (UMIN000031951). Haematological, clinical, functional, and pharmacotherapeutic parameters were evaluated at baseline and at weeks 4 and 12 after initiation of benralizumab. Twenty-six patients were enrolled between May 2018 and March 2019. Both asthma quality of life questionnaire (AQLQ) score and asthma control test (ACT) score showed significant improvement over the study period. Forced expiratory volume in 1.0 second (FEV1) showed a significant increase at week 12 (baseline: 1.57 L; week 12: 1.75 L). Blood eosinophil and basophil counts were significantly decreased at week 12 compared to baseline. At week 12, the dose of regular oral corticosteroids (OCS) was significantly decreased from baseline as was the number of patients on need-based OCS. Benralizumab had no significant effect on fractional exhaled nitric oxide (FeNO) levels and total immunoglobulin E levels. Only one patient experienced mild headache during benralizumab therapy. In this study, benralizumab conferred clinically significant benefits in patients with severe asthma with no short-term severe adverse events.
Sections du résumé
BACKGROUND
BACKGROUND
Benralizumab is a humanized, fucosylated, monoclonal antibody that targets the interleukin 5 (IL-5) α receptor. Several phase III trials have shown that benralizumab can significantly reduce the incidence of acute exacerbations and improve lung function in patients with severe asthma. However, there is a paucity of data from clinical practice. In this prospective study, we evaluated the effectiveness and safety of benralizumab for severe asthma in clinical practice.
METHODS
METHODS
This was a prospective, open-label, single-arm, single-center study in patients with severe asthma in clinical practice (UMIN000031951). Haematological, clinical, functional, and pharmacotherapeutic parameters were evaluated at baseline and at weeks 4 and 12 after initiation of benralizumab.
RESULTS
RESULTS
Twenty-six patients were enrolled between May 2018 and March 2019. Both asthma quality of life questionnaire (AQLQ) score and asthma control test (ACT) score showed significant improvement over the study period. Forced expiratory volume in 1.0 second (FEV1) showed a significant increase at week 12 (baseline: 1.57 L; week 12: 1.75 L). Blood eosinophil and basophil counts were significantly decreased at week 12 compared to baseline. At week 12, the dose of regular oral corticosteroids (OCS) was significantly decreased from baseline as was the number of patients on need-based OCS. Benralizumab had no significant effect on fractional exhaled nitric oxide (FeNO) levels and total immunoglobulin E levels. Only one patient experienced mild headache during benralizumab therapy.
CONCLUSIONS
CONCLUSIONS
In this study, benralizumab conferred clinically significant benefits in patients with severe asthma with no short-term severe adverse events.
Identifiants
pubmed: 32395482
doi: 10.21037/atm.2020.04.01
pii: atm-08-07-438
pmc: PMC7210162
doi:
Types de publication
Journal Article
Langues
eng
Pagination
438Informations de copyright
2020 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.04.01). The authors have no conflicts of interest to declare.
Références
Allergol Int. 2019 Apr;68(2):167-171
pubmed: 30878568
Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23
pubmed: 19892860
N Engl J Med. 2017 Sep 7;377(10):965-976
pubmed: 28877019
Allergy. 2007 Jun;62(6):591-604
pubmed: 17508962
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Lancet. 2016 Oct 29;388(10056):2115-2127
pubmed: 27609408
Lancet. 2016 Oct 29;388(10056):2128-2141
pubmed: 27609406
Allergol Int. 2017 Apr;66(2):163-189
pubmed: 28196638
Respir Med Case Rep. 2019 Feb 19;26:292-295
pubmed: 30859062
Drug Discov Today. 2011 Dec;16(23-24):1084-91
pubmed: 21930234
N Engl J Med. 2017 Jun 22;376(25):2448-2458
pubmed: 28530840
J Allergy Clin Immunol. 2016 May;137(5):1317-24
pubmed: 27155028
Respir Med. 2016 Feb;111:21-9
pubmed: 26775606
J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353.e2
pubmed: 20513525
N Engl J Med. 2014 Sep 25;371(13):1198-207
pubmed: 25199059
Eur Respir J. 2019 Jun 27;53(6):
pubmed: 31249014
Asthma Res Pract. 2017 Jan 6;3:1
pubmed: 28078100
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Mini Rev Med Chem. 2008 Jun;8(7):647-56
pubmed: 18537720
Respir Med. 2019 Jan;146:10-17
pubmed: 30665506
Allergy. 2019 Nov;74(11):2181-2190
pubmed: 31095758
Expert Opin Investig Drugs. 2017 Mar;26(3):357-366
pubmed: 28085503
J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):909-916
pubmed: 28689841